No wonder they are upset by the slogan ‘tax the rich’. Despite their wealth increasing 81% since 2020, they need our emotional support now more than ever Won’t anyone think of the poor, poor, billionaires? Their endless money can buy them political power, but it can’t buy them love. Instead of being worshipped by the hoi polloi, titans of industry are denounced! Despised! Disrespected! Insert anot...
No wonder they are upset by the slogan ‘tax the rich’. Despite their wealth increasing 81% since 2020, they need our emotional support now more than ever Won’t anyone think of the poor, poor, billionaires? Their endless money can buy them political power, but it can’t buy them love. Instead of being worshipped by the hoi polloi, titans of industry are denounced! Despised! Disrespected! Insert another D-word of your own! Thankfully, class solidarity is strong among the super-rich. Steve Roth bravely brought attention to the plight of his fellow billionaires during a recent earnings call. “I consider the phrase ‘tax the rich’ … spit out with anger and contempt by politicians … to be just as hateful as some disgusting racial slurs,” the Vornado Realty Trust CEO said. Continue reading...
Spencer Platt/Getty Images News New York City Mayor Zohran Mamdani has abandoned his controversial proposal to raise property taxes, according to a media report published Tuesday. Mamdani had previously pitched a nearly 10% property tax increase as leverage to secure additional funding from Governor Kathy Hochul. The proposal faced widespread opposition, including from City Council Speaker Julie M...
Spencer Platt/Getty Images News New York City Mayor Zohran Mamdani has abandoned his controversial proposal to raise property taxes, according to a media report published Tuesday. Mamdani had previously pitched a nearly 10% property tax increase as leverage to secure additional funding from Governor Kathy Hochul. The proposal faced widespread opposition, including from City Council Speaker Julie Menin and other council members who would have needed to approve any increase. The decision to ditch the proposed tax hike is expected to appear in the mayor’s executive budget released Tuesday, marking a significant shift in his approach to closing a two-year deficit, Bloomberg reported, citing a person familiar with the matter. The reversal comes alongside a major concession from Albany: Hochul and Mamdani said in a joint statement the state will provide $4B in new support to help address the city’s budget gap. Additionally, Hochul has proposed a pied-à-terre tax targeting expensive second homes in the city, though implementation details remain under negotiation. If the city's property taxes were raised, it would have been the first such hike in more than two decades. And such a move would likely lead to higher rents, as landlords pass through the costs to tenants, and may push businesses away from the city. Mamdani has characterized the city’s financial challenges as “a generational fiscal crisis” comparable to the Great Recession. While he has consistently advocated for higher taxes on wealthy residents and corporations, those proposals have met resistance from Hochul. The property tax increase represented one of the few budget remedies the city could pursue without state approval. New York-exposed REITs include SL Green Realty ( SLG ), Vornado Realty Trust ( VNO ), Equity Residential ( EQR ), Empire State Realty Trust ( ESRT ) and LXP Industrial Trust ( LXP ). Dear readers : We recognize that politics often intersects with the financial news of the day, so we invite you...
Sofiia Petrova/iStock via Getty Images The U.S. government is proposing a new legal pathway that would allow employers to offer fertility benefits to their employees outside the normal health insurance plans. The proposed rule will permit employers to offer healthcare coverage to treat infertility or related reproductive health conditions, subject to a lifetime benefits cap of $120K for plan years...
Sofiia Petrova/iStock via Getty Images The U.S. government is proposing a new legal pathway that would allow employers to offer fertility benefits to their employees outside the normal health insurance plans. The proposed rule will permit employers to offer healthcare coverage to treat infertility or related reproductive health conditions, subject to a lifetime benefits cap of $120K for plan years starting after 2028. Under the rule, the U.S. Department of Labor would include fertility treatments in a new category of limited excepted benefits, for which certain components of the Affordable Care Act and other federal healthcare coverage laws don’t apply. The initiative builds on an executive order issued by President Donald Trump in February that called for policy recommendations on expanding access to fertility services, such as in vitro fertilization, which can cost $12,000 to $25,000 per cycle. Shares of fertility benefits provider Progyny ( PGNY ) closed higher last week ahead of the announcement by the U.S. departments of labor, health and human services, and treasury on Sunday. More on Progyny Progyny, Inc. 2026 Q1 - Results - Earnings Call Presentation Progyny, Inc. (PGNY) Q1 2026 Earnings Call Transcript Progyny, Inc. (PGNY) Presents at Barclays 28th Annual Global Healthcare Conference Transcript Progyny anticipates 2026 revenue of $1.365B-$1.405B while raising adjusted EBITDA to $232M-$244M Progyny Non-GAAP EPS of $0.50 beats by $0.06, revenue of $328.5M beats by $1.99M
Leila Melhado/iStock Editorial via Getty Images MercadoLibre ( MELI ) shares continued to weaken technically after another sharp decline pushed the Latin American e-commerce giant below a key support level tied to its multiyear rally. MELI closed Monday at $1,557.30, falling beneath the 50% Fibonacci retracement of its 2022-to-2025 advance. The move marked a significant breakdown for traders track...
Leila Melhado/iStock Editorial via Getty Images MercadoLibre ( MELI ) shares continued to weaken technically after another sharp decline pushed the Latin American e-commerce giant below a key support level tied to its multiyear rally. MELI closed Monday at $1,557.30, falling beneath the 50% Fibonacci retracement of its 2022-to-2025 advance. The move marked a significant breakdown for traders tracking the stock’s longer-term momentum after it previously failed to hold the 23.6% and 38.2% retracement zones. The latest drop extended a broader selloff from MELI’s 2025 highs above $2,500, placing the stock firmly in the lower half of its post-2022 trading range. Still, the decline appeared to attract at least one high-profile buyer. Investor Michael Burry confirmed on his Substack that he purchased a new full position in MercadoLibre last week in the “$1600s” after the company’s post-earnings decline. Burry, known for predicting the 2008 housing crash, did not elaborate on the size of the position or his longer-term thesis. For technical traders, the next major level sat near the 61.8% retracement in the mid-$1,300 range. Holding above that zone could preserve the broader uptrend despite recent damage. A decisive break below it, however, would raise the risk that the stock’s multi-year bull run had fully unraveled. Here is the chart (it is on a weekly basis) Seeking Alpha More on MercadoLibre MercadoLibre's Margins Are Falling - And That's Bullish MercadoLibre Q1: The Selloff Is A Gift MercadoLibre, Inc. 2026 Q1 - Results - Earnings Call Presentation Michael Burry buys MercadoLibre on its post-earnings weakness Tech stocks lead Nasdaq with Datadog emerging as highest weekly gainer
Nvidia (NVDA) reports first quarter earnings results on Wednesday, May 20. B. Riley Wealth chief market strategist Art Hogan, Yahoo Finance Senior Business Reporter Ines Ferré, and Yahoo Finance Senior Reporter Brooke DiPalma join Yahoo Finance Executive Editor Brian Sozzi to discuss their expectations for the print, highlighting why Nvidia needs to knock it out of the park.
Nvidia (NVDA) reports first quarter earnings results on Wednesday, May 20. B. Riley Wealth chief market strategist Art Hogan, Yahoo Finance Senior Business Reporter Ines Ferré, and Yahoo Finance Senior Reporter Brooke DiPalma join Yahoo Finance Executive Editor Brian Sozzi to discuss their expectations for the print, highlighting why Nvidia needs to knock it out of the park.
Amazon (AMZN) is launching 30-minute deliveries throughout US cities as part of its Prime Now service, with plans to make this available in most areas 24 hours a day. Yahoo Finance Tech Editor Dan Howley discusses this new service and what it means for the broader express delivery space, especially as more companies employ the use of delivery robots.
Amazon (AMZN) is launching 30-minute deliveries throughout US cities as part of its Prime Now service, with plans to make this available in most areas 24 hours a day. Yahoo Finance Tech Editor Dan Howley discusses this new service and what it means for the broader express delivery space, especially as more companies employ the use of delivery robots.
Global Coal Demand Surges As Middle East Energy Crisis Deepens Authored by Tsvetana Paraskova via Oilprice.com, Global coal shipments and imports surged in March and April as buyers scrambled for fuel amid massively disrupted oil and gas supply from the Middle East. The trend has been accelerating in recent weeks, and global coal imports are on track to reach their third-highest monthly level on r...
Global Coal Demand Surges As Middle East Energy Crisis Deepens Authored by Tsvetana Paraskova via Oilprice.com, Global coal shipments and imports surged in March and April as buyers scrambled for fuel amid massively disrupted oil and gas supply from the Middle East. The trend has been accelerating in recent weeks, and global coal imports are on track to reach their third-highest monthly level on record, according to estimates by analytics platform Kpler cited by the Financial Times . In the wake of the worst oil and gas supply disruption in history , coal is back in demand, so much so that even countries and regions that believed coal use was in an irreversible terminal decline have boosted imports. For example, last month coal shipments to South Korea, Japan, and the European Union surged by 27% from a year earlier, data from BIMCO, the world’s biggest shipowners’ association, said last week. The Asian importers and the European bloc are scrambling for alternatives to gas supply from the Middle East, currently trapped behind the Strait of Hormuz or not produced at all in Qatar, which halted LNG production as early as on March 2 and two weeks later sustained damages to the world’s largest LNG complex, Ras Laffan, from Iranian missile strikes. “The closure of the Strait of Hormuz has disrupted LNG shipments out of the Persian Gulf and has contributed to an 8% y/y drop in global seaborne LNG shipments in April,” BIMCO said. South Korea has pushed back the retirement of coal-fired power generation capacity amid the oil and gas shock caused by the Middle East war. Europe, for its part, is currently losing the competition with Asia for spot LNG supply, at a time when it needs to fill gas storage sites ahead of the next winter. Energy security concerns are shifting policy responses, accelerating coal usage across key Asian and European markets, and delaying coal plant retirements, analysts at Wood Mackenzie say . Tyler Durden Tue, 05/12/2026 - 11:05
Final close brings together Canadian, UK, and international investors, underscoring global confidence in Photonic’s distributed quantum computing leadership Source: Photonic Inc. Photonic Inc.'s modular, scalable, distributed quantum computer and high-connectivity Entanglement First™ architecture leverages a unique qubit modality, optically-linked silicon spin qubits, to enable powerful computatio...
Final close brings together Canadian, UK, and international investors, underscoring global confidence in Photonic’s distributed quantum computing leadership Source: Photonic Inc. Photonic Inc.'s modular, scalable, distributed quantum computer and high-connectivity Entanglement First™ architecture leverages a unique qubit modality, optically-linked silicon spin qubits, to enable powerful computation, efficient error correction, and seamless integration with existing data center and telecom enviro
All the protocols that health experts like me look for have been followed. But outbreaks on cruise ships are notoriously hard to control Prof Devi Sridhar is chair of global public health at the University of Edinburgh Hantavirus: the disease you wish you’d never heard of, as visions of the Covid pandemic flash through your head. I’ve seen lots of breathless coverage and some bizarre takes on soci...
All the protocols that health experts like me look for have been followed. But outbreaks on cruise ships are notoriously hard to control Prof Devi Sridhar is chair of global public health at the University of Edinburgh Hantavirus: the disease you wish you’d never heard of, as visions of the Covid pandemic flash through your head. I’ve seen lots of breathless coverage and some bizarre takes on social media, so I imagine many people are confused as to what’s going on. Let me start by saying that this isn’t the Covid pandemic – only Covid was Covid. Previous hantavirus outbreaks have been contained (although none were on a cruise ship). So, for now, the risk to the general public is low – colleagues and I are still carrying on as normal and watching to see whether new infections arise outside the original cruise ship group . Those new infections would be the key step-change determining whether we see further spread and higher-risk public health alerts – or whether we’re at the end of this outbreak. Prof Devi Sridhar is chair of global public health at the University of Edinburgh, and the author of How Not to Die (Too Soon) Continue reading...
Earnings Call Insights: Acurx Pharmaceuticals (ACXP) Q1 2026 Management View "On March 9, '26, we issued a press release announcing that we're starting up a ground-breaking ibezapolstat clinical trial program in patients with recurrent CDI or rCDI, that has the potential to shift the paradigm of treatment and prevention of recurrent C. diff from 2 agents to just 1 or ibezapolstat." (CEO David Luci...
Earnings Call Insights: Acurx Pharmaceuticals (ACXP) Q1 2026 Management View "On March 9, '26, we issued a press release announcing that we're starting up a ground-breaking ibezapolstat clinical trial program in patients with recurrent CDI or rCDI, that has the potential to shift the paradigm of treatment and prevention of recurrent C. diff from 2 agents to just 1 or ibezapolstat." (CEO David Luci) "This new trial begins with an open-label pilot study" and is designed to "inform elements of a planned active controlled Phase III registration trial in the rCDI indication" following results from "the open-label 20-patient trial." (CEO Luci) "We're very excited about the FDA's recent announcement... that a 1-trial requirement will be FDA's new default standard... such as the opportunity to seek marketing approval for the acute CDI population with 1 pivotal clinical trial." (CEO Luci) "On April 16, 2026, the company announced the closing of a registered direct offering of 825,085 shares" at "$3.03 per share" and issued "unregistered short-term warrants to purchase up to 1,650,170 shares" with an "exercise price of $2.78 per share"; management said the related resale registration statement "is now effective." (CEO Luci) "The company ended the quarter with cash totaling $9.3 million, compared to $7.6 million as of December 31, 2025." (CFO Robert Shawah) "The company reported a net loss of $1.7 million or $0.62 per diluted share" and "[had] 3,389,106 shares outstanding as of March 31, 2026." (CFO Shawah) Outlook "Acurx clinical program in the broader acute CDI patient population is ready to advance to Phase III international pivotal clinical trials." (CEO Luci) "We've scheduled a meeting... discuss this with the FDA" regarding whether the agency’s one-trial framework can apply to ibezapolstat, and "at first pass, we don't see anything that will require a change in our pivotal trial design, which is already agreed to, with the FDA." (Executive chairman Robert DeLuccia) "This...
(RTTNews) - Rare disease drugmaker Agios Pharmaceuticals Inc. (AGIO) on Tuesday announced the submission of a supplemental New Drug Application, or sNDA, to the U.S. Food and Drug Administration seeking accelerated approval of mitapivat for the treatment of sickle cell disease.
(RTTNews) - Rare disease drugmaker Agios Pharmaceuticals Inc. (AGIO) on Tuesday announced the submission of a supplemental New Drug Application, or sNDA, to the U.S. Food and Drug Administration seeking accelerated approval of mitapivat for the treatment of sickle cell disease.